Merhaba, Turkey: Opportunity Knocks


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

Product Description

As the largest pharmaceutical market in the Middle East and the fastest growing in the Mediterranean region, Turkey presents some exciting opportunities for the pharmaceutical market.
Consumption of pharmaceuticals in Turkey totals around $8 billion, with 50% of these drugs being manufactured domestically and  about 70% of this manufacturing is done by foreign companies, according to consulting firm Egon Zehnder International.
But companies in Turkey also manufacture products for export and in 2010 the total value of pharmaceutical industry exports to Europe and the United States reached…

Healthcare in Turkey

Dr. Sule Mene. CEO, Mene ­Research, which was the first approved CRO in Turkey by the Turkish Ministry of Health and conducts studies ranging from Phase I to Phase IV. For more information, visit
Peter J. Pitts. President of the Center for Medicine in the ­Public Interest and Senior ­Partner, Director of Regulatory Affairs and Health Policy, Porter Novelli. The Center for ­Medicine in the Public ­Interest is a nonprofit medical issues ­research group that is partially funded by the pharma ­industry. For more ­information, visit Porter Novelli is a global public relations firm. For more information visit
Sven Schmidt. Bayer HealthCare ­Representative and Pharmaceuticals Country Division Head in Turkey, Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading innovative companies in the healthcare and medical products industry. For more information, visit
Murat Yesildere. Managing Partner, Egon Zehnder International, a global consultancy with sector specialists in ­financial services, consumer, life sciences, technology, communications, industrial, services, ­private capital, and sovereign wealth funds. For more information, visit